Our study also found that risk scores were significantly correlated with expression levels of PD-1, PD-L1, CTLA4, and CD19, suggesting that the four immune checkpoints may be potential immunotherapy targets for ccRCC. The gene discussed is CTLA4; the disease is nonpapillary renal cell carcinoma.